Gentian Violet
CAS 548-62-9
Gentian Violet (CAS 548-62-9) is a Phase 4 pharmaceutical compound with 27 bioactivity targets and 16 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 14222.321485714285 nM | 135 | - |
| - | IC50 | 6087.422068965517 nM | 57 | - |
| - | GI50 | 183.05563636363635 nM | 55 | - |
| - | MIC | 216.1601923076923 ug.mL-1 | 52 | - |
| - | AC50 | 11642.908823529413 nM | 34 | - |
| - | Ki | 1175.12 nM | 25 | - |
| - | EC50 | 96.215 nM | 2 | - |
| - | IC50 | 7.5 ug.mL-1 | 1 | - |
| - | Kd | 830 nM | 1 | - |
| Mu-type opioid receptor GPCR |
Ki | 6.06 | - | Homo sapiens |
| D(1A) dopamine receptor GPCR |
Ki | 5.809 | - | Homo sapiens |
| D(2) dopamine receptor GPCR |
Ki | 5.975 | - | Homo sapiens |
| Adenosine receptor A2a GPCR |
Ki | 5.724 | - | Homo sapiens |
| Alpha-2A adrenergic receptor GPCR |
Ki | 6.697 | - | Homo sapiens |
| Cytochrome P450 3A4 Enzyme |
IC50 | 5.44 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2A GPCR |
Ki | 6.124 | - | Homo sapiens |
| Alpha-2B adrenergic receptor GPCR |
Ki | 6.241 | - | Homo sapiens |
| D(3) dopamine receptor GPCR |
Ki | 6.55 | - | Homo sapiens |
| Histamine H2 receptor GPCR |
Ki | 5.945 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M1 GPCR |
Ki | 6.578 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M2 GPCR |
Ki | 6.294 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M3 GPCR |
Ki | 6.037 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M4 GPCR |
Ki | 6.854 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M5 GPCR |
Ki | 6.416 | - | Homo sapiens |
| Alpha-2C adrenergic receptor GPCR |
Ki | 6.562 | - | Homo sapiens |
| Sodium-dependent dopamine transporter Transporter |
Ki | 5.49 | - | Homo sapiens |
| Cytochrome P450 2D6 Enzyme |
IC50 | 6.084 | - | Homo sapiens |
| Adenosine receptor A3 GPCR |
Ki | 5.628 | - | Homo sapiens |
| Alpha-1D adrenergic receptor GPCR |
Ki | 6.012 | - | Homo sapiens |
| Kappa-type opioid receptor GPCR |
Ki | 6.21 | - | Homo sapiens |
| Acetylcholinesterase Enzyme |
IC50 | 5.233 | - | Homo sapiens |
| Epidermal growth factor receptor Kinase |
IC50 | 6.325 | - | Homo sapiens |
| Tyrosine-protein kinase Fyn Kinase |
IC50 | 5.668 | - | Homo sapiens |
| Substance-K receptor GPCR |
Ki | 6.252 | - | Homo sapiens |
| Androgen receptor Transcription factor |
Ki | 5.43 | - | Rattus norvegicus |
| Alpha-1B adrenergic receptor GPCR |
Ki | 5.701 | - | Rattus norvegicus |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| GENTIAN VIOLET | 4778 | SU | MTHSPL |
| gentian violet | 4778 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Gentian Violet used for in pharmaceutical contexts?
Gentian Violet (CAS 548-62-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Gentian Violet?
Gentian Violet has 16 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Drug ineffective, Drug resistance, Ear infection, Hallucination, Intentional product use issue. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Gentian Violet also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Basic Violet 3 with EU status "prohibited".
What clinical phase is Gentian Violet in?
Gentian Violet is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Gentian Violet?
Gentian Violet has 36 bioactivity rows in this page query. Rendered target entries include Mu-type opioid receptor, D(1A) dopamine receptor, D(2) dopamine receptor, Adenosine receptor A2a, Alpha-2A adrenergic receptor.